Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Hisanori Shimizu"'
Publikováno v:
SAGE Open Medicine, Vol 11 (2023)
Objectives: Many patients with hormone-receptor positive breast cancer undergo prolonged treatment. However, the long-term patient quality of life assessment has not been examined. Using community pharmacists’ assistance is one method for assessing
Externí odkaz:
https://doaj.org/article/0b2a27f2905e4ed9a05222c97fa92fad
Autor:
Yoshikazu Tateai, Kazuyoshi Kawakami, Minori Teramae, Naoki Fukuda, Takashi Yokokawa, Kazuo Kobayashi, Naoki Shibata, Wataru Suzuki, Hisanori Shimizu, Shunji Takahashi, Masato Ozaka, Naoki Sasahira, Satoko Hori, Masakazu Yamaguchi
Publikováno v:
PLoS ONE, Vol 18, Iss 11, p e0294320 (2023)
BackgroundLenvatinib is an oral anticancer medication used to treat radioiodine-refractory thyroid cancer and unresectable hepatocellular carcinoma. The purpose of this study is to evaluate lenvatinib adherence by patients and to identify factors ass
Externí odkaz:
https://doaj.org/article/b4c46abab72a478f8786e1e944661312
Autor:
Hisanori Shimizu, Kenichi Suzuki, Takeshi Uchikura, Daiki Tsuji, Takeharu Yamanaka, Hironobu Hashimoto, Koichi Goto, Reiko Matsui, Nobuhiko Seki, Toshikazu Shimada, Shunya Ikeda, Naoki Ikegami, Toshihiro Hama, Nobuyuki Yamamoto, Tadanori Sasaki
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 4, Iss 1, Pp 1-9 (2018)
Abstract Background We conducted an economic assessment using test data from the phase III TRIPLE study, which examined the efficacy of a 5-hydroxytryptamine 3 receptor antagonist as part of a standard triplet antiemetic regimen including aprepitant
Externí odkaz:
https://doaj.org/article/5b0a5c8ba430476091d421c82a65f915
Autor:
Hisanori Shimizu
Publikováno v:
YAKUGAKU ZASSHI. 143:233-236
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56bbab931c5a51b1e08b4c543abe1068
https://doi.org/10.1248/yakushi.22-00160-5
https://doi.org/10.1248/yakushi.22-00160-5
Publikováno v:
The Showa University Journal of Medical Sciences. 34:27-32
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::527f0cc37df35c6f0ec44ec34a58360c
https://doi.org/10.15369/sujms.34.27
https://doi.org/10.15369/sujms.34.27
Autor:
Satoshi Yuge, Ryota Tsukioka, Katsuaki Miyahara, Kenichi Suzuki, Takenori Ichimura, Hisanori Shimizu, Tomonobu Yoshimura, Hayato Murata, Keisuke Kado, Chiaki Ogawa, Hisanaga Nomura
Publikováno v:
Die Pharmazie. 77(6)
Background: Patients who develop severe side-effects when taking high-risk drugs may have a significantly reduced health-related quality of life (QOL); therefore, it is important to identify changes in health-related QOL in these patients. This study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb58c591212db71b0e95ff7ed50d1334
https://pubmed.ncbi.nlm.nih.gov/35751159
https://pubmed.ncbi.nlm.nih.gov/35751159
Autor:
Hisanori Shimizu, Tomohiro Ojima, Chie Yamamoto, Kenji Kasuno, Hideki Kimura, Masayuki Iwano, Naoki Takahashi, Seigaku Hayashi, Izumi Itoh
Publikováno v:
Internal Medicine
Tofacitinib is a new small-molecule inhibitor of the JAK/STAT signaling pathway used to treat rheumatoid arthritis. We herein report a case of IgA vasculitis apparently caused by tofacitinib. A 67-year-old woman with rheumatoid arthritis developed Ig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d585760fd05dafe33fe35ba075868eb5
http://europepmc.org/articles/PMC7118374
http://europepmc.org/articles/PMC7118374
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Toshikazu Shimada, Nobuhiko Seki, Shunya Ikeda, Naoki Ikegami, Takeharu Yamanaka, Takeshi Uchikura, Reiko Matsui, Tadanori Sasaki, Hironobu Hashimoto, Nobuyuki Yamamoto, Kenichi Suzuki, Koichi Goto, Daiki Tsuji, Toshihiro Hama, Hisanori Shimizu
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 4, Iss 1, Pp 1-9 (2018)
Journal of Pharmaceutical Health Care and Sciences
Journal of Pharmaceutical Health Care and Sciences
Background We conducted an economic assessment using test data from the phase III TRIPLE study, which examined the efficacy of a 5-hydroxytryptamine 3 receptor antagonist as part of a standard triplet antiemetic regimen including aprepitant and dexam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::368558398e570f9ee3fa0151c4b14bd1
http://link.springer.com/article/10.1186/s40780-018-0128-9
http://link.springer.com/article/10.1186/s40780-018-0128-9
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 47(3)
The aim of this study is to assess prophylactic prescriptions for febrile neutropenia(FN)caused by chemotherapy.We retrospectively surveyed prophylactic antibiotic prescriptions administered to 930 cancer treatment naive outpatients at Showa Universi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7a9f99e4cf0d4164dd02ba5e3e7cad00
https://pubmed.ncbi.nlm.nih.gov/32381911
https://pubmed.ncbi.nlm.nih.gov/32381911